2021³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ : 2021-04-28±³À°ÀÏÀÚ : 2021-04-28
±³À°Àå¼Ò : ¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ (¿ÀÇÁ¶óÀÎ: ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ 2Ãþ ÇѶóȦ ¿Ü)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2021³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-3473-0284
À̸ÞÀÏ :
kda@derma.or.kr ±³À°Á¾·ù : ÇǺΰú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 20 ½Ã°£ 37ºÐ
¼¼ºÎ¼ö°·á : 500,000¿ø
ºñ°í ¿ÀÇÁ¶óÀÎ Á¤È¸¿ø 70,000 ÁØȸ¿ø 30,000 / ¿Â¶óÀÎ Á¤È¸¿ø 50,000 ÁØȸ¿ø20,000 ¸¸65¼¼ ÀÌ»ó ¸éÁ¦ / ºñȸ¿ø 500,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
ÈÞ½Ä 04-28 12:30~13:00 Coffee Break ()
ÈÞ½Ä 04-28 15:00~15:30 Coffee Break ()
±âŸ 04-28 ÇѶóȦ 1~3 13:15~13:20 1. Introduction ¹Úõ¿í(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 13:20~13:35 2. Behcet ÀÌÀº¼Ò(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 14:00~14:25 1. Biologics Á¶¼ºÁø(¼¿ïÀÇ´ë)
Åä·Ð 04-28 ÇѶóȦ 1~3 14:25~14:30 2. Q&A ()
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 14:30~14:55 3. Other drugs and drug candidates ÀÌÁöÇö(°¡Å縯ÀÇ´ë)
Åä·Ð 04-28 ÇѶóȦ 1~3 14:55~15:00 4. Q&A ()
±âŸ 04-28 ¹éµÎȦ 1 15:30~15:33 Introduction Chair()
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 15:33~15:43 1. What is the optimal way of isotretinoin treatment in acne? (cumulative dosing vs long-term low dose) Is cumulative dosing more optimal? Initial presentation for Pros ÀÌ»óÁÖ(¿¬¼¼½ºÅ¸ÇǺΰú)
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 15:43~15:53 1. What is the optimal way of isotretinoin treatment in acne? (cumulative dosing vs long-term low dose) Is cumulative dosing more optimal? Initial presentation for Cons ÀÌÈñÁ¤(Â÷ÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 15:53~15:58 Rebuttal by Pros ()
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 15:58~16:03 Rebuttal by Cons ()
Åä·Ð 04-28 ¹éµÎȦ 1 16:03~16:15 Discussion with audience ()
±âŸ 04-28 ¹éµÎȦ 1 16:15~16:18 Introduction Chair()
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 16:18~16:28 2. Is confirmatory testing for onychomycosis necessary for treatment? Initial presentation for Pros ½Å¹Î°æ(°æÈñÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 16:28~16:38 2. Is confirmatory testing for onychomycosis necessary for treatment? Initial presentation for Cons ÀÌ¿µº¹(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 16:38~16:43 Rebuttal by Pros ()
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 16:43~16:48 Rebuttal by Cons ()
Åä·Ð 04-28 ¹éµÎȦ 1 16:48~17:00 Discussion with audience ()
±âŸ 04-28 ¹éµÎȦ 1 17:00~17:02 1. Introduction Chair()
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 17:02~17:24 2. Epidermolysis bullosa simplex ÀÌ»óÀº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 17:24~17:46 3. Nummular eczema ±èÇý¿ø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 17:46~18:08 4. Morphea ³ë¹Ì·É(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 18:08~18:30 5. Skin cancer À±¼÷Á¤(Àü³²ÀÇ´ë)
±âŸ 04-28 ¹éÁ¦È¦ 1~5 10:30~10:33 1. Introduction Chair()
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 10:33~10:48 2. Adipose stem cell exosome (ASCE)-based regenerative therapeutics & aesthetics Á¶º´¼º((ÁÖ)¿¢¼ÒÄÚ¹ÙÀÌ¿À ´ëÇ¥)
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 10:48~11:03 3. Exosomes: a novel player for atopic dermatitis? ¹Ú±Í¿µ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 11:03~11:18 4. Basic and clinical hair research for exosome ¹Úº´Ã¶(´Ü±¹ÀÇ´ë)
Åä·Ð 04-28 ¹éÁ¦È¦ 1~5 11:18~11:30 5. Q&A ()
±âŸ 04-28 ÇѶóȦ 1~3 16:30~16:33 1. Introduction Chair()
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 16:33~16:50 2. Update on skin manifestations of COVID-19 ¹æöȯ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 16:50~17:10 3. Optimizing care for patients requiring biologics in COVID-19 pandemic ±èµ¿Çö(Â÷ÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 17:10~17:20 4. Skin lesion associated with practicing personal hygiene ÇѺ°(À»ÁöÀÇ´ë)
Åä·Ð 04-28 ÇѶóȦ 1~3 17:20~17:30 5. Q&A ()
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 09:30~09:42 1. Á¶Á÷ °Ë»ç, ¸é¿ªÇü±¤°Ë»ç ±è¹Î¼ö(Áß¾Óº¸Èƺ´¿ø)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 09:42~09:54 2. Áø±Õ ÀÌÁöÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 09:54~10:06 3. ±¤°Ë»ç ±èÁ¤¼ö(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 10:06~10:18 4. øÆ÷°Ë»ç ÀÌ°¡¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 10:18~10:30 5. ´õ¸ð½ºÄÚÇÇ°Ë»ç ¹®Á¦È£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 10:30~10:42 6. ½ºÅ×·ÎÀÌµå ¼³Á¤Àº(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 10:42~10:54 7. Ç×Áø±ÕÁ¦/Ç×»ýÁ¦ ³ªÂùÈ£(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 10:54~11:06 8. ¸é¿ª¾ïÁ¦Á¦ Á¤º¸¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 11:06~11:18 9. ·¹Æ¼³ëÀÌµå ¹Ú°æ´ö(°æºÏÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 11:18~11:30 10. Ç×È÷½ºÅ¸¹ÎÁ¦ ±èµµ¿µ(¿¬¼¼ÀÇ´ë)
±âŸ 04-28 ÇѶóȦ 1~3 15:30~15:35 1. Introduction Chair()
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 15:35~16:20 2. ÇǺιÝÀÀ°Ë»çÀÇ È°¿ë ½ÀÁø¿¡¼ ¾à¹°¹ßÁøÀ» °ÅÃÄ ÇǺλö¼ÒÁúȯ±îÁö Àֿ̾µ(µ¿±¹ÀÇ´ë)
Åä·Ð 04-28 ÇѶóȦ 1~3 16:20~16:30 3. Q&A ()
±âŸ 04-28 ¹éµÎȦ 1 14:00~14:05 1. Overview Chair()
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 14:05~14:30 2. Glossary of dermatopathology ¿À»óÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éµÎȦ 1 14:30~14:55 3. Immunohistochemical staining ¹ÚÇýÁø(ÀÎÁ¦ÀÇ´ë)
Åä·Ð 04-28 ¹éµÎȦ 1 14:55~15:00 4. Q&A ()
±âŸ 04-28 ¹éµÎȦ 2 09:30~19:35 1. Overview Chair()
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 09:35~09:50 2. Recent issues regarding ocular safety ¿ì°æÀÎ(¼º±Õ°üÀÇ´ë ¾È°úÇб³½Ç)
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 09:50~10:05 3. Easy to miss: Practical things in clinics (interactive session) ÀÌÁ¾Èñ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 10:05~10:20 4. Updates: Safety-related regulation À¯ÈÁ¤(°í·ÁÀÇ´ë)
Åä·Ð 04-28 ¹éµÎȦ 2 10:20~10:30 5. Q&A ()
±âŸ 04-28 ¹éÁ¦È¦ 1~5 09:30~09:35 1. Introduction Chair()
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 09:35~10:20 2. ¿¬±¸ÀÚ°¡ ¾Ë¾Æ¾ß ÇÒ ÃâÆÇÀ±¸® ±èÀ¯¼±(ÀÎÁ¦ÀÇ´ë ³»°úÇб³½Ç/ÀÇÆíÇù ÃâÆÇÀ±¸®À§¿ø)
Åä·Ð 04-28 ¹éÁ¦È¦ 1~5 10:20~10:30 3. Q&A ()
±âŸ 04-28 ÇѶóȦ 1~3 13:35~13:40 1. Introduction Chair()
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 13:40~13:55 2. The skin microbiota in dermatology ±èÇý¼º(°¡Å縯ÀÇ´ë)
Åä·Ð 04-28 ÇѶóȦ 1~3 13:55~14:00 3. Q&A ()
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 17:00~17:25 1. ³Ä¡¼º »ö¼Ò Ä¡·áÀÇ ³ëÇÏ¿ì ÃÖõÇÊ(´ëÇÑÇǺΰúÀÇ»çȸ Á¤º¸ÀÌ»ç/ÇϴôÀ³¦ÇǺΰú)
Åä·Ð 04-28 ¹éµÎȦ 2 17:25~17:30 Q&A ()
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 17:30~17:55 2. Å»¸ðÄ¡·áÀÇ ³ëÇÏ¿ì Á¶Ç×·¡(´ëÇÑÇǺΰúÀÇ»çȸ Ãѹ«ÀÌ»ç/¿ÀÅ´½ºÇǺΰú)
Åä·Ð 04-28 ¹éµÎȦ 2 17:55~18:00 Q&A ()
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 18:00~18:25 3. ½Ç¸®ÇÁÆÃÀÇ ³ëÇÏ¿ì Á¤Âù¿ì(´ëÇÑÇǺΰúÇÐȸ Àǹ«ÀÌ»ç/JFÇǺΰú)
Åä·Ð 04-28 ¹éµÎȦ 2 18:25~18:30 Q&A ()
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 15:30~15:50 1. CRISPR-Cas9 based genome editing ÀÓÁ¤¹Î(¿¬¼¼ÀÇ´ë ¾à¸®Çб³½Ç)
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 15:50~16:10 2. How to acquire successful scRNAseq data in dermatology ±èÇöÁ¦(Áö´Ï³Ê½º ÀÌ»ç)
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 16:10~16:30 3. 3D skin imaging ÀÌÇر¤(P&K ÇǺÎÀӻ󿬱¸¼¾ÅÍ ´ëÇ¥)
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 16:30~16:50 4. Downstream bioinformatic analysis of your tranome data using public databases ±èűÕ(¿¬¼¼ÀÇ´ë)
Åä·Ð 04-28 ¹éµÎȦ 2 16:50~17:00 5. Q&A ()
±âŸ 04-28 ÇѶóȦ 1~3 11:30~11:33 1. Introduction Chair(Chair)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 11:33~11:58 2. Topical ivermectin, the newest addition to the armamentarium for rosacea treatment Á¶¼Ò¿¬(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-28 ÇѶóȦ 1~3 11:58~12:23 3. Effective topical treatment for preventing acne scar ÃÖÀ¯¼º(¿ï»êÀÇ´ë)
Åä·Ð 04-28 ÇѶóȦ 1~3 12:23~12:30 4. Q&A ()
±âŸ 04-28 ¹éµÎȦ 2 10:30~10:33 1. Introduction Chair(Chair)
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 10:33~11:18 2. Making the next steps in psoriatic arthritis the dermatologist ±èº´¼ö(ºÎ»êÀÇ´ë)
Åä·Ð 04-28 ¹éµÎȦ 2 11:18~11:30 3. Q&A ()
±âŸ 04-28 ¹éµÎȦ 2 14:00~14:03 1. Introduction Chair(Chair)
±³À°½Ã°£ 04-28 ¹éµÎȦ 2 14:03~14:48 2. JAK Pathway and MOA in dermatology ¼¿µÁØ(Ãæ³²ÀÇ´ë)
Åä·Ð 04-28 ¹éµÎȦ 2 14:48~15:00 3. Q&A ()
±âŸ 04-28 ¹éÁ¦È¦ 1~5 14:00~14:05 1. Overview Chair()
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 14:05~14:16 2. Diagnosis - Pathologist È«¼ø¾ï(Áß¾ÓÀÇ´ë º´¸®Çб³½Ç)
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 14:16~14:27 3. Non-surgical I - Internist ±è¹Ì¼Ò(¼¿ï´ëº´¿ø Ç÷¾×Á¾¾ç³»°ú)
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 14:27~14:38 4. Non-surgical II - Dermatologist ±èÀ¯Âù(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 14:38~14:49 5. Surgery - Dermato-surgeon ±èÀÏȯ(°í·ÁÀÇ´ë)
Åä·Ð 04-28 ¹éÁ¦È¦ 1~5 14:49~15:00 6. Q&A ()
±âŸ 04-28 ¹éÁ¦È¦ 1~5 15:30~15:35 1. Overview Chair()
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 15:35~15:50 2. Diet and weight ±èűÕ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 15:50~16:05 3. Moisturizer and skin care È«½ÂÇÊ(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 16:05~16:20 4. Pruritus ÀÌ°©¼®(Áß¾ÓÀÇ´ë)
Åä·Ð 04-28 ¹éÁ¦È¦ 1~5 16:20~16:30 5. Q&A ()
±âŸ 04-28 ¹éÁ¦È¦ 1~5 16:30~16:35 1. Overview Chair()
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 16:35~16:50 2. Cellular metabolism-related cosmetic ingredients À̵¿ÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 16:50~17:05 3. Skin constituents-related cosmetic ingredients È«½ÂÇÊ(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 04-28 ¹éÁ¦È¦ 1~5 17:05~17:20 4. Antioxidant-related cosmetic ingredients ÀÌÈñÁ¤(Â÷ÀÇ´ë)
Åä·Ð 04-28 ¹éÁ¦È¦ 1~5 17:20~17:30 5. Q&A ()